Tricida Announces Multiple Data Presentations to Be Given at the Virtual National Kidney Foundation 2021 Spring Clinical Meet...

Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer, a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD), announced today that multiple presentations on the impact of metabolic acidosis and CKD and data on veverimer will be given at the National Kidney Foundation 2021 Spring Clinical Meetings taking place from April 6 to 10, 2021.

Data from Tricida-sponsored studies on the impact of metabolic acidosis and CKD will include the following: 

Title:	Low Serum Bicarbonate is Associated with Excess Mortality in Kidney Transplant Recipients
Author:	V. Mathur et al.
Link:	View poster here
Poster #:	275
Title:	Low Serum Bicarbonate is Associated with Graft Failure and Major Cardiovascular Outcomes in Kidney Transplant Recipients
Author:	V. Mathur et al.
Link:	View poster here
Poster #:	276
Title:	Increasing Serum Bicarbonate Is Associated with Reduced Risk of Adverse Kidney Outcomes in Patients with CKD and Metabolic Acidosis
Author:	N. Tangri et al.
Link:	View poster here
Poster #:	279
Tricida will also present data on veverimer:
Title:	Evaluation of Potential Physicochemical Interactions of Orally Administered, Non-absorbed Ion-exchange Resins with Veverimer
Author:	S. Tabakman et al.
Link:	View poster here
Poster #:	278

About Tricida

Tricida, Inc. is a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer, a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with CKD. Tricida is currently conducting a renal outcomes clinical trial, VALOR-CKD, to determine if veverimer slows progression of CKD in patients with metabolic acidosis and CKD. There are no FDA-approved treatments for chronic metabolic acidosis, a condition commonly caused by CKD that is believed to accelerate the progression of kidney deterioration. It is estimated to pose a health risk to approximately three million patients with CKD in the United States.

For more information about Tricida, please visit www.Tricida.com.

Contact:Jackie Cossmon, IRCTricida, Inc.Senior Vice President of Investor Relations and [e-mail]

Source: Tricida, Inc.